SCHEMBL25792156

SCHEMBL25792156

COc1cccnc1-c1ccc(N)cc1F

nearest known ligand 0.56

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KIT P10721 2/20 0.56
ALOX5AP P20292 3/20 0.42
FEN1 P39748 3/20 0.42
PDE7A Q13946 2/20 0.42
S100A4 P26447 1/20 0.39
PIK3CA P42336 2/20 0.39
CCNT1 O60563 1/20 0.38
CDK9 P50750 1/20 0.38
PLAU P00749 1/20 0.38
IMPDH2 P12268 1/20 0.38
IMPDH1 P20839 1/20 0.38
NSD2 O96028 1/20 0.38
CASP6 P55212 1/20 0.38
G6PD P11413 1/20 0.38
PDGFRB P09619 1/20 0.37
PDGFRA P16234 1/20 0.37
IDO1 P14902 1/20 0.37
BACE1 P56817 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15674427 0.86 MAPK14 (0.44) KITALOX5APFEN1CCNT1CDK9
SCHEMBL25792160 0.82 ALDH1A1 (0.46) KITPDE7AS100A4CCNT1CDK9
SCHEMBL25394314 0.81 SQOR (0.43) ALOX5APS100A4PIK3CACCNT1CDK9
SCHEMBL31387690 0.81 SQOR (0.43) ALOX5APS100A4PIK3CACCNT1CDK9
SCHEMBL15674586 0.80 ALOX5AP (0.46) ALOX5APFEN1
SCHEMBL15674510 0.80 MAP4K1 (0.45) S100A4IDO1
SCHEMBL4817970 0.78 LMNA (0.56) CCNT1CDK9
SCHEMBL15674227 0.77 SYK (0.44) CCNT1CDK9PDGFRBPDGFRA
SCHEMBL4654900 0.76 ALOX5AP (0.50) KITALOX5APFEN1PDE7A
SCHEMBL31002040 0.75 CCR9 (0.39) ALOX5APFEN1S100A4CCNT1CDK9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230219965-A1 NITROGEN-CONTAINING FUSED BICYCLIC COMPOUNDS AND THEIR USE AS UBIQUITIN-SPECIFIC-PROCESSING PROTEASE 1 (USP1) INHIBITORS KSQ Therapeutics, Inc. 2023-07-13 US disclosed
US-20230219965-A1 NITROGEN-CONTAINING FUSED BICYCLIC COMPOUNDS AND THEIR USE AS UBIQUITIN-SPECIFIC-PROCESSING PROTEASE 1 (USP1) INHIBITORS KSQ Therapeutics, Inc. 2023-07-13 US disclosed
US-20230219965-A1 NITROGEN-CONTAINING FUSED BICYCLIC COMPOUNDS AND THEIR USE AS UBIQUITIN-SPECIFIC-PROCESSING PROTEASE 1 (USP1) INHIBITORS KSQ Therapeutics, Inc. 2023-07-13 US disclosed
EP-4161494-A1 NITROGEN-CONTAINING FUSED BICYCLIC COMPOUNDS AND THEIR USE AS UBIQUITIN-SPECIFIC-PROCESSING PROTEASE 1 (USP1) INHIBITORS KSQ Therapeutics, Inc. (US) 2023-04-12 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230219965-A1 NITROGEN-CONTAINING FUSED BICYCLIC COMPOUNDS AND THEIR USE AS UBIQUITIN-SPECIFIC-PROCESSING PROTEASE 1 (USP1) INHIBITORS USP1, USP8, USP7 KIT 2390/4885ALOX5AP 4648/4885FEN1 1419/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.